NCI’s IMAT program invites R33 applications to advance and validate innovative molecular and cellular analysis technologies that improve targeting, probing, and measurement of cancer biology for basic, translational, and clinical research. Projects must include quantitative performance measures, demonstrate prior feasibility, and exclude clinical trials. This opportunity supports tools with broad applicability to early detection, diagnostics, treatment development, epidemiology, and reduction of cancer health disparities.
Eligibility Criteria
-
Eligible: higher-education institutions; nonprofits; for-profits (incl. small businesses); government and tribal entities; foreign organizations; non-U.S. components of U.S. organizations
-
PD/PI must have an eRA Commons ID
-
Focus on technology advancement/validation (not hypothesis-driven biology) with quantitative performance measures
-
Non-responsive: whole-body/in vivo imaging instrumentation, biomarker discovery/validation, drugs/therapies, software-only projects, clinical trials
Funding Details
-
Mechanism: R33 (Phase II)
-
Anticipated awards: ~10 (FY2026), total 4,300,000 USD
-
Budget: up to 300,000 USD in direct costs per year
-
Project period: up to 3 years
-
Clinical trial: not allowed
-
FON: RFA-CA-25-002 (companions: RFA-CA-25-001, RFA-CA-25-003, RFA-CA-25-004)
Deadline
-
Due date: October 3, 2025 (5:00 PM local time)
Where to go for further information
-
Program contact: Kelly Crotty, Ph.D. — [email protected]